In partnership with
How Jennifer Aniston’s LolaVie brand grew sales 40% with CTV ads
For its first CTV campaign, Jennifer Aniston’s DTC haircare brand LolaVie had a few non-negotiables. The campaign had to be simple. It had to demonstrate measurable impact. And it had to be full-funnel.
LolaVie used Roku Ads Manager to test and optimize creatives — reaching millions of potential customers at all stages of their purchase journeys. Roku Ads Manager helped the brand convey LolaVie’s playful voice while helping drive omnichannel sales across both ecommerce and retail touchpoints.
The campaign included an Action Ad overlay that let viewers shop directly from their TVs by clicking OK on their Roku remote. This guided them to the website to buy LolaVie products.
Discover how Roku Ads Manager helped LolaVie drive big sales and customer growth with self-serve TV ads.
The DTC beauty category is crowded. To break through, Jennifer Aniston’s brand LolaVie, worked with Roku Ads Manager to easily set up, test, and optimize CTV ad creatives. The campaign helped drive a big lift in sales and customer growth, helping LolaVie break through in the crowded beauty category.
Dear Sentinels
Postural Orthostatic Tachycardia Syndrome, or POTS if you prefer not to trip over syllables, has usually been diagnosed by its symptoms rather than its causes. Think heart rate shooting up when you stand, dizziness, fatigue, and brain fog that can leave people stuck in bed for years. But slapping a single label on it hides a much messier biological reality. Two patients might look identical on paper, but under the bonnet, their bodies could be up to entirely different tricks. No wonder so many drug trials for chronic conditions like this one quietly fizzle out. This gap between what we call a diagnosis and what’s actually going on inside is exactly where AI is starting to make itself useful. At Biocomputing 2026, a paper showed off a deep learning approach to classifying POTS patients using wearable ECG and accelerometer data, neatly sidestepping the discomfort and faff of the usual tilt-table exam. It’s a small but telling sign that, after years of being ignored and misunderstood, chronic illnesses like POTS might finally be getting the data-driven attention they deserve. Who knows, maybe soon we’ll have diagnoses that actually mean something.
But first we are off to see what the web has brought us this week.
